Brief: Vir Biotechnology Reports Positive Updated Phase 1 Results For Psma-Targeting, Pro-Xten Dual-Masked T-Cell Engager Vir-5500
23/02/2026 22:26
Feb 23 (Reuters) - Vir Biotechnology Inc VIR.O: VIR BIOTECHNOLOGY REPORTS POSITIVE UPDATED PHASE 1 RESULTS FOR PSMA-TARGETING, PRO-XTEN® DUAL-MASKED T-CELL ENGAGER VIR-5500 IN PATIENTS WITH METASTATIC PROSTATE CANCER VIR BIOTECHNOLOGY INC - VIR-5500 SHOWS FAVORABLE SAFETY PROFILE WITH NO DOSE-LIMITING TOXICITIES VIR BIOTECHNOLOGY INC: ADVANCING DOSE-EXPANSION COHORTS AND PLAN TO INITIATE OUR REGISTRATIONAL TRIAL IN 2027 VIR BIOTECHNOLOGY INC - DOSE-DEPENDENT ANTI-TUMOR ACTIVITY OBSERVED WITH VIR-5500 VIR BIOTECHNOLOGY: 82% PSA50 & 53% PSA90 DECLINES & RECIST-EVALUABLE OBJECTIVE RESPONSES IN ≥3,000 ΜG/KG Q3W DOSING COHORTS WITH VIR-5500 Source text: ID:nBw3qlpKDa Further company coverage: VIR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vir Biotechnology
See all newsVir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal
Vir Biotechnology gains after up to $1.9 billion licensing deal with Gilead
Brief: Vir Biotechnology Announces Psma-Targeted Pro-Xten® Dual-Masked T-Cell Engager Vir-5500 Received FDA Fast Track Designation For The Treatment Of Prostate Cancer
Brief: Vir Biotechnology Appoints David Liu As Chief Medical Officer
Vir Biotechnology rises after naming Theravance's Sawaf as CFO